Budapesti Szent Ferenc Korhaz
- Address
- lock Available on a paid plan
Cardiovascular Diseases Research
The clinical trial activity at Budapesti Szent Ferenc Korhaz is focused on cardiovascular diseases, with an emphasis on improving care for people at risk of serious heart-related events. The studies are exploring whether new approaches can better protect patients and support more effective prevention and treatment strategies.
- Atrial Fibrillation and stroke prevention
- Atherosclerotic cardiovascular disease and elevated lipoprotein(a)
- Testing new therapies aimed at reducing major cardiovascular complications
Research in this area is centered on evaluating treatment effectiveness in patients who may not be well served by standard options, while also looking at ways to lower the risk of heart attack, stroke, and related events.
Heart Rhythm and Thromboembolic Risk
This site is also involved in research on atrial fibrillation, a common heart rhythm disorder linked to a higher chance of ischemic stroke. The trials are designed to assess whether newer therapies can offer better protection for patients who are not suitable for standard oral anticoagulation.
- Reducing stroke risk in atrial fibrillation
- Evaluating alternatives for patients unsuitable for standard blood-thinning treatment
- Improving prevention of serious clot-related complications
The focus is on finding safer and more effective ways to manage clot-related risk in everyday cardiology practice.
Atherosclerotic Disease and Lipid-Related Research
Another key area of investigation at Budapesti Szent Ferenc Korhaz involves atherosclerotic cardiovascular disease and elevated lipoprotein(a), both important contributors to long-term heart risk. The trials are examining whether new treatment strategies can better reduce major coronary events.
- Coronary heart disease prevention
- Lowering the risk of myocardial infarction
- Assessing treatment impact on urgent revascularization needs
These studies aim to improve outcomes for patients with persistent cardiovascular risk despite current care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Budapesti Szent Ferenc Korhaz
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. | Amgen Inc. | Phase II | Not Recruiting | Mar 2023 | Oct 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 1 | Unknown | 2023-10-31 | 2023-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.